Trgovina Amicus - FOLD CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Pogoji trgovanja
| Razmik | 0.07 | ||||||||
|
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.025457% | ||||||||
|
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | 0.003235% | ||||||||
| Čas nočne pristojbine | 21:00 (UTC) | ||||||||
| Min. tržena količina | 1 | ||||||||
| Valuta | USD | ||||||||
| Kritje | 20% | ||||||||
| Borza | United States of America | ||||||||
| Provizija na trgovanje | 0% |
*Information provided by Capital.com
Amicus Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Ključni statistični podatki
| Predhodno. Zapri* | 10.57 |
| Odpri* | 10.37 |
| Enoletna sprememba* | -3.36% |
| Dnevni razpon* | 10.37 - 10.84 |
| Razpon 52 wk | 7.78-13.84 |
| Povprečni obseg (10 dni) | 2.32M |
| Povprečni obseg (3 meseci) | 52.01M |
| Tržna kapitalizacija | 3.56B |
| Razmerje P/E | -100.00K |
| Število delnic v obtoku | 284.58M |
| Prihodki | 336.79M |
| EPS | -0.70 |
| Dividenda (donosnost v %) | N/A |
| Beta | 0.80 |
| Datum naslednjega zaslužka | Aug 2, 2023 |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 10.76 | 0.27 | 2.57% | 10.49 | 10.87 | 10.30 |
| Jun 28, 2022 | 10.57 | -0.13 | -1.21% | 10.70 | 10.97 | 10.42 |
| Jun 27, 2022 | 10.77 | 0.06 | 0.56% | 10.71 | 11.04 | 10.43 |
| Jun 24, 2022 | 11.08 | 0.11 | 1.00% | 10.97 | 11.09 | 10.43 |
| Jun 23, 2022 | 10.88 | 1.06 | 10.79% | 9.82 | 10.99 | 9.82 |
| Jun 22, 2022 | 9.95 | 0.30 | 3.11% | 9.65 | 10.30 | 9.62 |
| Jun 21, 2022 | 9.84 | 0.36 | 3.80% | 9.48 | 10.15 | 9.38 |
| Jun 17, 2022 | 9.32 | 0.86 | 10.17% | 8.46 | 9.42 | 8.44 |
| Jun 16, 2022 | 8.36 | 0.48 | 6.09% | 7.88 | 8.44 | 7.79 |
| Jun 15, 2022 | 8.14 | 0.35 | 4.49% | 7.79 | 8.30 | 7.79 |
| Jun 14, 2022 | 7.90 | 0.20 | 2.60% | 7.70 | 8.02 | 7.70 |
| Jun 13, 2022 | 7.86 | -0.17 | -2.12% | 8.03 | 8.17 | 7.75 |
| Jun 10, 2022 | 8.33 | 0.17 | 2.08% | 8.16 | 8.48 | 8.16 |
| Jun 9, 2022 | 8.53 | 0.09 | 1.07% | 8.44 | 8.90 | 8.44 |
| Jun 8, 2022 | 8.74 | 0.43 | 5.17% | 8.31 | 8.86 | 8.26 |
| Jun 7, 2022 | 8.39 | 0.72 | 9.39% | 7.67 | 8.42 | 7.67 |
| Jun 6, 2022 | 7.85 | -0.28 | -3.44% | 8.13 | 8.27 | 7.76 |
| Jun 3, 2022 | 8.14 | 0.77 | 10.45% | 7.37 | 8.18 | 7.37 |
| Jun 2, 2022 | 7.73 | 0.22 | 2.93% | 7.51 | 7.78 | 7.45 |
| Jun 1, 2022 | 7.60 | 0.21 | 2.84% | 7.39 | 7.77 | 7.39 |
Amicus Events
| Čas (UTC) (UTC) | Država | Dogodek |
|---|---|---|
| Wednesday, August 2, 2023 | ||
| Čas (UTC) (UTC) 12:30 | Država US
| Dogodek Q2 2023 Amicus Therapeutics Inc Earnings Release Q2 2023 Amicus Therapeutics Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Čas (UTC) (UTC) 13:30 | Država US
| Dogodek Q3 2023 Amicus Therapeutics Inc Earnings Release Q3 2023 Amicus Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Letni
- Četrtletno
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Skupni prihodki | 329.233 | 305.514 | 260.886 | 182.237 | 91.245 |
| Prihodki | 329.233 | 305.514 | 260.886 | 182.237 | 91.245 |
| Celotni stroški prihodkov | 38.599 | 34.466 | 31.044 | 21.963 | 14.404 |
| Bruto dobiček | 290.634 | 271.048 | 229.842 | 160.274 | 76.841 |
| Celotni odhodki iz poslovanja | 541.353 | 512.205 | 515.16 | 526.898 | 420.022 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 213.041 | 192.71 | 156.407 | 169.861 | 127.2 |
| Raziskave in razvoj | 276.677 | 272.049 | 308.443 | 286.378 | 270.902 |
| Depreciation / Amortization | 5.342 | 6.209 | 8.846 | 4.775 | 4.216 |
| Nenavadni odhodki (prihodki) | 6.616 | 0.257 | 7.276 | 40.624 | 0 |
| Other Operating Expenses, Total | 1.078 | 6.514 | 3.144 | 3.297 | 3.3 |
| Prihodki iz poslovanja | -212.12 | -206.691 | -254.274 | -344.661 | -328.777 |
| Prihodki (odhodki) od obresti, neto Neoperativni | -34.095 | -31.962 | -19.199 | -8.623 | -14.68 |
| Drugo, neto | 4.176 | -2.901 | -0.781 | -2.626 | -5.632 |
| Čisti dobiček pred obdavčitvijo | -242.039 | -241.554 | -274.254 | -355.91 | -349.089 |
| Čisti dobiček po davkih | -236.568 | -250.46 | -276.852 | -356.388 | -349.095 |
| Čisti dobiček pred dodatnimi postavkami | -236.568 | -250.46 | -276.852 | -356.388 | -349.095 |
| Čisti dobiček | -236.568 | -250.46 | -276.852 | -356.388 | -348.995 |
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -236.568 | -250.46 | -276.852 | -356.388 | -349.095 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -236.568 | -250.46 | -276.852 | -356.388 | -348.995 |
| Popravljen čisti dobiček | -236.568 | -250.46 | -276.852 | -356.388 | -348.995 |
| Popravljene ponderirane povprečne delnice | 289.057 | 271.422 | 258.867 | 240.421 | 185.79 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.81841 | -0.92277 | -1.06947 | -1.48235 | -1.87898 |
| Popravljen normalizirani dobiček na enoto čistega dobička | -0.80354 | -0.92215 | -1.0512 | -1.37252 | -1.52912 |
| Skupaj izredne postavke | 0 | 0.1 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Skupni prihodki | 86.27 | 88.096 | 81.691 | 80.731 | 78.715 |
| Prihodki | 86.27 | 88.096 | 81.691 | 80.731 | 78.715 |
| Celotni stroški prihodkov | 6.942 | 9.384 | 13.436 | 8.197 | 7.582 |
| Bruto dobiček | 79.328 | 78.712 | 68.255 | 72.534 | 71.133 |
| Celotni odhodki iz poslovanja | 123.906 | 130.424 | 115.531 | 141.344 | 154.054 |
| Celotna prodaja/splošni/upravni stroški Odhodki | 73.957 | 54.274 | 47.272 | 53.379 | 58.116 |
| Raziskave in razvoj | 41.499 | 63.871 | 52.97 | 78.319 | 81.517 |
| Depreciation / Amortization | 1.257 | 1.311 | 1.286 | 1.334 | 1.411 |
| Other Operating Expenses, Total | 0.251 | 1.584 | 0.567 | 0.115 | -1.188 |
| Prihodki iz poslovanja | -37.636 | -42.328 | -33.84 | -60.613 | -75.339 |
| Prihodki (odhodki) od obresti, neto Neoperativni | -9.698 | -9.123 | -9.057 | -7.901 | -8.014 |
| Drugo, neto | -5.885 | -18.628 | 13.634 | 7.268 | 1.902 |
| Čisti dobiček pred obdavčitvijo | -53.219 | -70.079 | -29.263 | -61.246 | -81.451 |
| Čisti dobiček po davkih | -52.932 | -55.865 | -33.286 | -62.157 | -85.26 |
| Čisti dobiček pred dodatnimi postavkami | -52.932 | -55.865 | -33.286 | -62.157 | -85.26 |
| Čisti dobiček | -52.932 | -55.865 | -33.286 | -62.157 | -85.26 |
| Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -52.932 | -55.865 | -33.286 | -62.157 | -85.26 |
| Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -52.932 | -55.865 | -33.286 | -62.157 | -85.26 |
| Popravljen čisti dobiček | -52.932 | -55.865 | -33.286 | -62.157 | -85.26 |
| Popravljene ponderirane povprečne delnice | 291.337 | 289.706 | 289.224 | 291.971 | 288.482 |
| Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.18169 | -0.19283 | -0.11509 | -0.21289 | -0.29555 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Popravljen normalizirani dobiček na enoto čistega dobička | -0.18169 | -0.19283 | -0.11509 | -0.21289 | -0.28064 |
| Nenavadni odhodki (prihodki) | 0 | 0 | 0 | 0 | 6.616 |
- Letni
- Četrtletno
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 423.816 | 596.834 | 579.469 | 520.073 | 551.096 |
| Denarna sredstva in kratkoročne naložbe | 293.595 | 482.496 | 483.269 | 452.74 | 504.152 |
| Denarna sredstva in ustrezniki | 148.813 | 245.197 | 163.24 | 142.837 | 79.749 |
| Kratkoročne naložbe | 144.782 | 237.299 | 320.029 | 309.903 | 424.403 |
| Celotne terjatve, neto | 66.196 | 52.672 | 46.923 | 33.284 | 21.962 |
| Accounts Receivable - Trade, Net | 66.196 | 52.672 | 46.923 | 33.284 | 21.962 |
| Total Inventory | 23.816 | 26.818 | 19.556 | 14.041 | 8.39 |
| Prepaid Expenses | 40.209 | 34.848 | 29.721 | 20.008 | 16.592 |
| Total Assets | 724.167 | 905.14 | 886.52 | 850.207 | 789.951 |
| Property/Plant/Equipment, Total - Net | 60.312 | 63.082 | 67.159 | 81.02 | 11.375 |
| Property/Plant/Equipment, Total - Gross | 82.593 | 82.964 | 89.22 | 103.966 | 27.046 |
| Accumulated Depreciation, Total | -22.281 | -19.882 | -22.061 | -22.946 | -15.671 |
| Goodwill, Net | 197.797 | 197.797 | 197.797 | 197.797 | 197.797 |
| Intangibles, Net | 23 | 23 | 23 | 23 | 23 |
| Other Long Term Assets, Total | 19.242 | 24.427 | 19.095 | 28.317 | 6.683 |
| Total Current Liabilities | 139.018 | 145.975 | 129.676 | 128.812 | 86.125 |
| Accounts Payable | 15.413 | 21.513 | 17.063 | 21.722 | 6.606 |
| Accrued Expenses | 88.66 | 95.21 | 88.442 | 68.852 | 36.188 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Other Current Liabilities, Total | 34.945 | 29.252 | 24.171 | 8.55 | 5.5 |
| Total Liabilities | 601.12 | 597.771 | 600.14 | 373.782 | 447.039 |
| Total Long Term Debt | 391.99 | 389.357 | 389.254 | 149.505 | 321.74 |
| Long Term Debt | 391.99 | 389.357 | 389.254 | 149.505 | 321.74 |
| Deferred Income Tax | 4.939 | 4.93 | 4.896 | 5.051 | 6.465 |
| Other Liabilities, Total | 65.173 | 57.509 | 76.314 | 90.414 | 32.709 |
| Total Equity | 123.047 | 307.369 | 286.38 | 476.425 | 342.912 |
| Common Stock | 2.815 | 2.808 | 2.65 | 2.598 | 1.942 |
| Additional Paid-In Capital | 2664.74 | 2595.42 | 2308.58 | 2227.23 | 1740.06 |
| Retained Earnings (Accumulated Deficit) | -2532.41 | -2295.84 | -2033.07 | -1756.22 | -1399.16 |
| Unrealized Gain (Loss) | -0.116 | -0.27 | -0.185 | 0.04 | -0.427 |
| Other Equity, Total | -11.989 | 5.251 | 8.412 | 2.785 | 0.495 |
| Total Liabilities & Shareholders’ Equity | 724.167 | 905.14 | 886.52 | 850.207 | 789.951 |
| Total Common Shares Outstanding | 281.108 | 278.913 | 262.063 | 255.418 | 189.384 |
| Payable/Accrued | 29.688 | 37.831 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Kratkoročna sredstva skupaj | 399.697 | 423.816 | 458.539 | 497.643 | 518.9 |
| Denarna sredstva in kratkoročne naložbe | 267.109 | 293.595 | 354.7 | 386.841 | 411.195 |
| Denarna sredstva in ustrezniki | 160.602 | 148.813 | 277.592 | 235.639 | 233.317 |
| Kratkoročne naložbe | 106.507 | 144.782 | 77.108 | 151.202 | 177.878 |
| Celotne terjatve, neto | 68.178 | 66.196 | 52.303 | 52.556 | 52.421 |
| Accounts Receivable - Trade, Net | 68.178 | 66.196 | 52.303 | 52.556 | 52.421 |
| Total Inventory | 27.004 | 23.816 | 13.272 | 20.879 | 24.324 |
| Prepaid Expenses | 37.406 | 40.209 | 38.264 | 37.367 | 30.96 |
| Total Assets | 700.519 | 724.167 | 759.528 | 800.589 | 826.938 |
| Property/Plant/Equipment, Total - Net | 59.889 | 60.312 | 62.32 | 64.104 | 62.053 |
| Property/Plant/Equipment, Total - Gross | 54.307 | 53.059 | 55.786 | 55.845 | 55.51 |
| Accumulated Depreciation, Total | -22.901 | -22.281 | -23.337 | -22.188 | -20.966 |
| Goodwill, Net | 197.797 | 197.797 | 197.797 | 197.797 | 197.797 |
| Intangibles, Net | 22.964 | 23 | 23 | 23 | 23 |
| Other Long Term Assets, Total | 20.172 | 19.242 | 17.872 | 18.045 | 25.188 |
| Total Current Liabilities | 138.385 | 139.018 | 164.65 | 164.625 | 129.699 |
| Accounts Payable | 24.965 | 15.413 | 12.046 | 23.113 | 22.914 |
| Accrued Expenses | 100.752 | 102.188 | 132.771 | 122.246 | 87.634 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 12.668 | 21.417 | 19.833 | 19.266 | 19.151 |
| Total Liabilities | 597.946 | 601.12 | 626.963 | 627.164 | 588.321 |
| Total Long Term Debt | 392.658 | 391.99 | 391.319 | 390.652 | 389.994 |
| Long Term Debt | 392.658 | 391.99 | 391.319 | 390.652 | 389.994 |
| Deferred Income Tax | 0 | 4.939 | 4.93 | 4.93 | 4.93 |
| Other Liabilities, Total | 66.903 | 65.173 | 66.064 | 66.957 | 63.698 |
| Total Equity | 102.573 | 123.047 | 132.565 | 173.425 | 238.617 |
| Common Stock | 2.82 | 2.815 | 2.813 | 2.811 | 2.809 |
| Additional Paid-In Capital | 2691.84 | 2664.74 | 2645.37 | 2631.11 | 2617.94 |
| Retained Earnings (Accumulated Deficit) | -2585.34 | -2532.41 | -2476.54 | -2443.26 | -2381.1 |
| Unrealized Gain (Loss) | -0.201 | -0.116 | -0.354 | -0.637 | -0.608 |
| Other Equity, Total | -6.543 | -11.989 | -38.724 | -16.603 | -0.42 |
| Total Liabilities & Shareholders’ Equity | 700.519 | 724.167 | 759.528 | 800.589 | 826.938 |
| Total Common Shares Outstanding | 283.301 | 281.108 | 280.887 | 280.457 | 280.134 |
- Letni
- Četrtletno
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Čisti prihodki/začetna postavka | -236.568 | -250.46 | -276.852 | -356.388 | -348.995 |
| Denarna sredstva iz poslovanja | -166.575 | -202.491 | -233.29 | -250.416 | -299.955 |
| Denarna sredstva iz poslovanja | 5.342 | 6.209 | 8.846 | 4.775 | 4.216 |
| Deferred Taxes | 0.009 | 0.034 | -0.155 | -1.415 | 0 |
| Nedenarne postavke | 104.522 | 70.664 | 66.935 | 91.002 | 49.551 |
| Denarna sredstva Plačane obresti | 34.358 | 30.468 | 24.683 | 16.966 | 7.5 |
| Spremembe v obratnem kapitalu | -39.88 | -28.938 | -32.064 | 11.61 | -4.727 |
| Denarna sredstva pri naložbenju | 92.316 | 78.761 | -13.579 | 95.153 | -121.2 |
| Kapitalski izdatki | -3.766 | -3.884 | -3.227 | -20.012 | -6.308 |
| Celotne druge postavke denarnih tokov pri naložbenju | 96.082 | 82.645 | -10.352 | 115.165 | -114.892 |
| Denarna sredstva pri financiranju | -7.463 | 212.073 | 262.858 | 217.502 | 450.775 |
| Postavke denarnega toka pri financiranju | -11.49 | -16.656 | -10.028 | 16.64 | -2.832 |
| Izdaja (odplačilo) delnic, neto | 4.31 | 229.208 | 42.282 | 201.282 | 307.345 |
| Izdaja (odplačilo) dolga, neto | -0.283 | -0.479 | 230.604 | -0.42 | 146.262 |
| Učinki deviznih tečajev | -14.619 | -5.049 | 3.83 | 1.729 | 1.518 |
| Neto sprememba denarnih sredstev | -96.341 | 83.294 | 19.819 | 63.968 | 31.138 |
| Cash Taxes Paid | 1.609 | 20.032 | 10.371 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -52.932 | -236.568 | -180.703 | -147.417 | -85.26 |
| Cash From Operating Activities | -18.069 | -166.575 | -85.803 | -74.177 | -58.315 |
| Cash From Operating Activities | 1.257 | 5.342 | 4.031 | 2.745 | 1.411 |
| Non-Cash Items | 41.697 | 104.522 | 79.442 | 55.954 | 37.389 |
| Cash Taxes Paid | 0.178 | 1.609 | 0.935 | 0.71 | 0.456 |
| Cash Interest Paid | 11.361 | 34.358 | 24.058 | 15.108 | 7.509 |
| Changes in Working Capital | -3.152 | -39.88 | 11.427 | 14.541 | -11.855 |
| Cash From Investing Activities | 36.255 | 92.316 | 159.02 | 84.505 | 58.213 |
| Capital Expenditures | -1.942 | -3.766 | -1.089 | -1.226 | -0.871 |
| Other Investing Cash Flow Items, Total | 38.197 | 96.082 | 160.109 | 85.731 | 59.084 |
| Cash From Financing Activities | -7.825 | -7.463 | -8.02 | -7.461 | -8.154 |
| Financing Cash Flow Items | -10.452 | -11.49 | -11.119 | -9.278 | -8.993 |
| Issuance (Retirement) of Stock, Net | 2.655 | 4.31 | 3.191 | 1.858 | 0.859 |
| Issuance (Retirement) of Debt, Net | -0.028 | -0.283 | -0.092 | -0.041 | -0.02 |
| Foreign Exchange Effects | 1.507 | -14.619 | -33.12 | -12.462 | -3.377 |
| Net Change in Cash | 11.868 | -96.341 | 32.077 | -9.595 | -11.633 |
| Deferred Taxes | -4.939 | 0.009 |
| Ime vlagatelja | Vrsta vlagatelja | Odstotek neporavnanih obveznosti | Delnice v lasti | Sprememba delnic | Datum imetništva | Ocena prometa |
|---|---|---|---|---|---|---|
| Perceptive Advisors LLC | Private Equity | 9.7208 | 27662917 | 20000 | 2023-03-31 | MED |
| Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 9.5932 | 27300000 | 500000 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.4244 | 26819529 | 323574 | 2023-03-31 | LOW |
| Redmile Group, LLC | Investment Advisor/Hedge Fund | 6.4471 | 18346861 | -1902928 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.2531 | 17794935 | -462246 | 2023-03-31 | LOW |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 4.7827 | 13610435 | -84114 | 2023-03-31 | LOW |
| Morgan Stanley & Co. LLC | Research Firm | 4.2773 | 12172065 | -2396638 | 2023-03-31 | MED |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.9114 | 11130885 | -954954 | 2023-03-31 | LOW |
| Palo Alto Investors LP | Hedge Fund | 3.6981 | 10524022 | 30300 | 2023-03-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 3.5087 | 9984901 | 1553949 | 2023-03-31 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.6408 | 7515041 | -592306 | 2023-03-31 | LOW |
| JP Morgan Asset Management | Investment Advisor | 2.5262 | 7188898 | 460005 | 2023-03-31 | LOW |
| Macquarie Investment Management | Investment Advisor | 2.5199 | 7171035 | 212988 | 2023-03-31 | LOW |
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 2.061 | 5865111 | -7089 | 2023-03-31 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.8976 | 5400086 | 2934928 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.807 | 5142407 | 251979 | 2023-03-31 | LOW |
| Fiera Capital Corporation | Investment Advisor/Hedge Fund | 1.7926 | 5101364 | -87793 | 2023-03-31 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 1.2392 | 3526407 | -473593 | 2023-03-31 | LOW |
| Boxer Capital, L.L.C. | Hedge Fund | 0.817 | 2325000 | 0 | 2023-03-31 | LOW |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.8065 | 2295225 | 20644 | 2023-03-31 | LOW |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com Group535K+
Borzni posredniki
87K+
Aktivne stranke mesečno
$113M+
Mesečni obseg naložb
$64M+
Dvigi vsak mesec
Kalkulator trgovanja
Izračunajte svoj hipotetični P&L, če bi trgovino s CFD odprli na določen datum (izberite datum) in jo zaprli na drug datum (izberite datum).
Trgovalna provizija
0
- 1:1
Vzvod
1:1
- 20
- 100
- 500
- 1000
- 10000
Naložbe
Velikost posla (finančni vzvod x naložba):
Odpiranje
Zapiranje
Kratka Dolga
Amicus Company profile
O družbi Amicus
Amicus Therapeutics, Inc. je globalno biotehnološko podjetje, ki se osredotoča na odkrivanje, razvoj in zagotavljanje zdravil za redke bolezni. V portfelju podjetja je Galafold (migalastat), ki je odobreno peroralno natančno zdravilo za ljudi s Fabryjevo boleznijo. Migalastat je pod trgovskim imenom Galafold odobren v Združenih državah Amerike, Evropski uniji, Združenem kraljestvu in na Japonskem. Njegov biološki program v pripravi je Amicus Therapeutics GAA (AT-GAA), ki je paradigma zdravljenja Pompejeve bolezni v klinični fazi. Ameriška uprava za hrano in zdravila (FDA) je za zdravilo AT-GAA za zdravljenje pozne oblike Pompejeve bolezni podelila oznako prebojne terapije (BTD). Njegovi programi vključujejo programe genskega zdravljenja redkih nevroloških lizosomskih motenj (LD), zlasti: CLN6, CLN3 in CLN1 Battenova bolezen, Pompejeva bolezen, Fabryjeva bolezen, motnja pomanjkanja CDKL5 (CDD), mukopolisaharidoza tipa IIIB (MPS IIIB) ter mukopolisaharidoza tipa IIIA (MPS IIIA).
| Industry: | Biotechnology & Medical Research (NEC) |
3675 Market Street
PHILADELPHIA
PENNSYLVANIA 19104
US
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 535.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com